IRON Stock Disc Medicine, Inc.
US · NasdaqGMLast in our picks 2026-10-20 — not in the current list; analysis below is from that screen
Rare-disease pipeline momentum and rising targets support catalyst-driven appreciation.
Future value: $120.00 (+52.03%) · 6-12 months
Signal breakdown
- ▸BMO raised target to $120 while maintaining Outperform.
- ▸Above 50-day MA (+10.37%)
- ▸Above 200-day MA — long-term uptrend
- ▸Volume 17.07× average — accumulation
- ▸~52% upside to price target
Is IRON a buy right now?
Trend: IRON is trading above the 50-day average (+4.59%), RSI 39 — neutral momentum, with a 3-month return of -0.13%.
Valuation & quality: Disc Medicine, Inc. trades on forward P/E -11.2, price-to-book 4.62; fundamentals show net margin 0.0%, return on equity -39.1%.
Analyst consensus: 12 analysts have a mean 12-month price target of $125.75 (+61.9% vs the last close; range $92.00 – $170.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 6) — Rare-disease pipeline momentum and rising targets support catalyst-driven appreciation.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -4.00% | +3.10% | +5.50% | +5.10% | +5.30% | +2.10% | -16.80% | +13.80% |
Fundamentals
Analyst price target
Technical signals
About Disc Medicine, Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
Sector: Healthcare · Industry: Biotechnology · United States · 165 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.